Total coronary heart disease
Beta‐blockers showed no clear difference in total coronary heart disease compared with renin‐angiotensin system inhibitors (low certainty).
1 finding from 1 review
Withdrawals due to adverse events
Beta‐blockers probably leads to higher withdrawal due to adverse effect compared with renin‐angiotensin system inhibitors (moderate certainty).
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 75 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 150 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 300 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 600 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 75 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 150 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 300 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 600 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diarrhoea ‐ Aliskiren 600 mg vs placebo · primary hypertension
The intervention may leads to higher diarrhoea ‐ Aliskiren 600 mg vs placebo (low certainty).
1 finding from 1 review
Intervention not reported
Effect on systolic blood pressure (mean difference in systolic blood pressure) · adults with primary hypertension
The intervention showed no clear difference in effect on systolic blood pressure (mean difference in systolic blood… (moderate certainty).
1 finding from 1 review
Intervention not reported
Effect on diastolic blood pressure (mean difference in diastolic blood pressure) · adults with primary hypertension
The intervention showed no clear difference in effect on diastolic blood pressure (mean difference in diastolic… (moderate certainty).
1 finding from 1 review
Intervention not reported
Any adverse event · adults with primary hypertension
The intervention showed no clear difference in any adverse event (low certainty).
1 finding from 1 review
Intervention not reported
Adverse event leading to withdrawal · adults with primary hypertension
The intervention showed no clear difference in adverse event leading to withdrawal (low certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Stroke · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in stroke compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in withdrawals due to adverse effects compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Intervention not reported
End of treatment SBP (over 12 weeks) · patients with primary hypertension
1 finding from 1 review